Active Surveillance
Active Surveillance is a clinical management strategy for low- or favorable‑risk localized prostate cancer in which curative treatment is intentionally deferred while the disease is closely monitored through protocolized assessments (e.g., PSA testing, digital rectal examination, imaging, and repeat biopsy) so that intervention is initiated only upon evidence of progression or reclassification to higher risk.
1.1K
Publications
63K
Citations
5.4K
Authors
1.4K
Institutions
Publications per year
2017–2026
474
1.1K
1–5 of 1.1K
5.4K
University of California, San Francisco, United States
78 publications · 7K citations
43
h-index
University of California, San Francisco, United States
51 publications · 5.5K citations
34
h-index
34
h-index
31
h-index
30
h-index
1–5 of 5.4K
1.4K
University of California, San Francisco
San Francisco, United States
44 h-index
359 publications
25K citations

Johns Hopkins University
Baltimore, United States
42 h-index
409 publications
35.9K citations

University of Toronto
Toronto, Canada
39 h-index
305 publications
25.1K citations
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, United States
38 h-index
279 publications
28.5K citations
Memorial Sloan Kettering Cancer Center
New York, United States
35 h-index
255 publications
20.1K citations
Erasmus MC
Rotterdam, The Netherlands
35 h-index
257 publications
23K citations
University of Michigan
Ann Arbor, United States
30 h-index
182 publications
10.1K citations

Sunnybrook Health Science Centre
Toronto, Canada
29 h-index
159 publications
27.8K citations
1–8 of 1.4K
162 publications · 10.5K citations
60
h-index
61 publications · 7K citations
46
h-index
108 publications · 5.1K citations
42
h-index
57 publications · 2K citations
28
h-index
27 publications · 2K citations
21
h-index
1–5